Hi there- I noticed you recently reviewed our compare products page. I want to reach out and see if you have any questions I could help answer. Can I make a suggestion? Many of our investors find success with MarketBeat All Access, and I’m willing to give you the opportunity to try it free for 30 days.
MarketBeat All Access is our premier research platform that includes MarketBeat Daily Premium, My MarketBeat, our suite of web-based research tools, and our premium research reports. With MarketBeat All Access, you will receive our real-time news feed and access to our database of more than 1,000,000 stock ratings and our proprietary brokerage rankings. You will also receive other exclusive benefits, including premium support, extended data export tools, and priority delivery of your morning newsletter. After your 30-day trial, if you are happy with the features and wish to continue your subscription, we will give you a $200.00 credit toward your MarketBeat All Access subscription. If you are interested in registering for MarketBeat All Access at the discounted rate, do it now by clicking the link below. Start My Free Trial to MarketBeat All Access. I’ll be honest, this is a really great deal, especially for the value that MarketBeat All Access offers. But don’t just take my word for it; trust what our satisfied subscribers have to say: "I use MarketBeat.com every day that the market is open to provide me with the most up-to-date financial data allowing me to support my investing decisions. There are multiple ways that you can use this resource, including the ability to personalize areas of interest and specific stock lists. I have tested several financial service companies, and this one is the best by far" - Ronald S. "MarketBeat offers an astute analysis of stocks and how they relate to the market as a whole. Their reports are concise and to the point. MarketBeat stands out as highly ethical, subjecting stocks and the broader market to the cold hard light of meticulous research. This allows me a high degree of confidence in their recommendations." -Dorothy L. If you are still hesitant about trying out our services, let me assure you there is no risk. You have nothing to lose but everything to gain. If after your 30-day trial you decide this service isn’t for you, simply cancel, and we won’t charge you. Upgrade to MarketBeat All Access Hope to hear from you soon! Matthew Paulson
MarketBeat P.S. If you have any additional questions, simply reply to this email, and our U.S.-based Customer Service team will be happy to help you.
Further Reading from MarketBeat 3 Stocks You'll Wish You Bought Before 2026Written by Chris Markoch. Published 12/3/2025. 
Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors have profited from the artificial intelligence (AI) trade in 2025. But several up-and-coming stocks in other sectors have also posted impressive gains this year. These three stocks are still relatively small — the largest market cap is just over $4 billion — yet they've made strong moves and illustrate the value of time in the market over trying to time the market. While headlines focus on Tesla's car sales, tech analyst Jeff Brown says the real story is Tesla's role in a $25 trillion AI revolution — one that Nvidia's CEO himself has called a "multi-trillion-dollar future industry" — and he's uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough. Click here now to see the full report If investors could see the future with absolute clarity, investing would be easy. The future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these names and had the patience to hold through rough patches are reaping the benefits today. And the rallies may not be finished. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently reported positive clinical data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. The company's pivotal Phase 3 VIKTORIA trial is underway, and some investors believe the company could receive U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those results, pushing CELC stock up more than 660%, with nearly all of those gains occurring since the end of July. At $99.30 as of this writing, the stock is within about 3% of its consensus price target. Jefferies raised its price target on Dec. 2 to $134 from $108. The largest risk is the cost of commercialization. However, in its most recent earnings report, Celcuity showed a strengthened balance sheet with $455 million in cash, cash equivalents, and short-term investments — up about 72% year-over-year (YOY). Management believes that cash will be sufficient until commercialization begins. Fintech Disruptor Turning Revenue Growth Into Real Momentum With traditional banks offering fewer appealing options for many consumers, Dave Inc. (NASDAQ: DAVE) has positioned itself well. The Los Angeles-based fintech is known for the Dave app, which provides affordable, transparent tools to help users avoid overdraft fees, budget better, and access short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS). DAVE stock is up 120% in 2025, and analysts see room to run. As of this writing, the stock trades at $208.24, while the consensus price target is $304.25 — about 46% upside. Some investors may be wary of the company's forward price-to-earnings (P/E) ratio of roughly 119x. But analysts forecast earnings growth of over 117% in the next 12 months, which could justify a premium valuation if the growth materializes. Resale Retail Winner Riding a Massive Consumer Shift It's been another challenging year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP stock is up more than 430% in 2025, despite a pullback of over 29% in the three months ending Dec. 1. The company operates an online consignment marketplace, a compelling model as many consumer budgets remain stretched. The thrift and resale market was a $49 billion industry in 2024 and is projected to grow to $74 billion by 2029. TDUP is the smallest of the three names here, and short interest exceeding 17% indicates active trading. Still, the company's Q3 report showed strong YOY revenue growth, record new-buyer acquisition, and a 37% YOY increase in orders. This could be a shorter-term trade for some investors, but younger consumers — who form ThredUp's core market — are likely to remain price-sensitive, supporting continued demand for resale. Analysts give TDUP a consensus price target of $12.50, about 68% above its closing price on Dec. 1.
| 
